Fresenius Kabi Oncology has received board’s approval for entering into contract R&D and manufacturing agreements with Fresenius Kabi Germany and its affiliates for future products without affecting existing product business and Intellectual Property Rights (IPRs).
The company received the approval at its board meeting held on May 26, 2011. The company has decided to enter into an agreement with the view to further leverage its R&D and manufacturing competencies. The company has also received an approval for entering into a distribution agreement with Fresenius Kabi India for selling and marketing its products in India.
Further, Fresenius Kabi Oncology has also received an approval for disinvestment of its entire shareholding in Fresenius Kabi Oncology Plc, UK - a wholly owned subsidiary of the company to Fresenius Kabi Germany and its affiliates. The agreements will come into effect after obtaining all necessary internal approvals and signing of the same, which can be expected in June 2011.
Fresenius Kabi Oncology is a leading Indian company for cancer research and anticancer products. The company uses the services of Dabur Research Foundation (DRF) for research and development activities. The pharma major market its products in various parts of the world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela and Mexico, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: